Co-Diagnostics

CODX

Capitalización de mercado USD 4.57 M

Existing Sputum Sample-Preparation Technology Provides Potential Foundation for Plague Diagnostics Draws on Rapid-Response Experience with COVID-19, Mpox and Ebola Supported by Expanded Manufacturing Infrastructure SALT LAKE CITY, Oct. 15, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today highlighted capabilities of its Co-Dx PCR Pro®* point-of-care platform that could be applied to plague diagnostics, should a public health need arise. The Company is monitoring developments following the October 2 death of a laboratory worker at a plague research institute in Irkutsk, Russia.

Ute Indian Tribe Mosquito Abatement Department to bring PCR-based mosquito surveillance testing in house SALT LAKE CITY, Oct. 8, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has received an order from the Ute Indian Tribe Mosquito Abatement Department for a full Vector Smart® mosquito surveillance laboratory installation. The order represents the Company's first complete Vector Smart laboratory installation for a Native American tribe and will enable the Tribe to perform PCR testing of mosquito pools in house.

New Executive Order prioritizes improved detection and calls for federal R&D programs for rapid diagnostics for mosquito- and tick-borne diseases Company to participate in October 9 Utah Global Health Leadership roundtable and four regional mosquito control conferences this fall SALT LAKE CITY, Oct. 7, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today highlighted the growing commercial momentum of its Vector Smart® mosquito surveillance business following the September 29, 2026 signing of Executive Order 14433, "Eliminating Disease-Carrying Pests and Restoring Enjoyment of the Great Outdoors" (the "Executive Order"). The Executive Order establishes a federal initiative focused on suppressing tick and mosquito populations and addressing vector-borne disease through improved detection, screening, prevention and health care interventions.

Ebola Assay in Development for Decentralized Testing on the Co-Dx PCR Platform SALT LAKE CITY, Oct. 6, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its upcoming participation at WHX Labs Johannesburg, taking place October 6-8, 2026, at the Gallagher Convention Centre in Johannesburg, South Africa. Attendees are invited to join Co-Dx at Booth # H3.L38, where the Company will showcase the Co-Dx PCR platform and the Co-Dx™ PCR MTB test*.

Events Bring Together Global Health Leaders to Examine Tuberculosis and Preparedness for the Next Respiratory Pandemic SALT LAKE CITY, Sept. 23, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that Seth Egan, Chief Commercialization Officer, will represent the Company at two global health events during the 81st Session of the United Nations General Assembly in New York City: UNOPS Hosted Partnerships Reception – September 23, 2026: The Company will attend a reception, convened by UN Under-Secretary-General and UNOPS Executive Director Jorge Moreira da Silva, that brings together UNOPS leadership with executives and board members from across its hosted partnerships, including the Stop TB Partnership.

Roundtable discussion, taking place in New York City, will examine the ongoing Ebola outbreak and technologies needed to strengthen future outbreak response. Co-Dx will join officials from the U.S. Department of State's Bureau of Global Health Security and Diplomacy and leaders from across the global health research and development community.

SALT LAKE CITY, Sept. 17, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will participate in the upcoming joint WHO/Unitaid/UNAIDS Annual Consultation Meeting.

Co-Diagnostics, Inc. (CODX) Shareholder/Analyst Call Transcript

Blood-based testing could open new markets for the Co-Dx® PCR platform, including HIV and hepatitis B and C Co-Diagnostics and ReadyGo target decentralized Ebola detection as the first application of their collaboration Combining GoCollect® sample preparation with Co-Dx PCR technology could bring blood-based molecular testing closer to patients Company to hold in-person press conference and live webcast today at 10:30 a.m. ET SALT LAKE CITY, Sept.

Media, analysts and investors are welcome to attend in person or via live webcast, Sept. 16 at 10:30 a.m.